Injection of Glatiramer Acetate Depot Results in T1 and T2 Lesion Reduction in Relapsing MS.

Published Date: 01 Mar 2023

Secondary results from a phase 3 study show that patients with multiple sclerosis receiving glatiramer acetate depot therapy have significantly fewer new T1 enhancing lesions and new, enlarging hyperintense T2 lesions.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Prostate cancer therapies: AI-based image analysis detects early organ damage

2.

In prostate cancer survivorship, sleep disturbances are underappreciated.

3.

An effective treatment for a rare but deadly form of cancer

4.

A Win for Molecularly Guided Therapy for Cancer of Unknown Primary

5.

Specialized imaging improves overall prostate cancer survival by identifying benefits of salvage radiotherapy


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot